CLAIMS

1. Ulipristal acetate or any metabolite thereof for use in the treatment of uterine fibroids in a therapeutically effective amount, wherein said ulipristal acetate or any metabolite thereof is to be administered in subsequent treatment periods and a treatment period lasts 2-6 months and each treatment period is followed by a drug-free period.
2. Ulipristal acetate or any metabolite thereof for use according to claim 1 wherein a treatment period lasts 2-4 months.
3. Ulipristal acetate or any metabolite thereof for use according to of any claims 1-2 wherein a treatment period lasts 12 weeks.
4. Ulipristal acetate or any metabolite thereof for use according to any claims 1-3 wherein a drug-free period comprises at least one menstruation cycle.
5. Ulipristal acetate or any metabolite thereof for use according to any of claims 1-4 wherein a drug-free period comprises at least two menstruation cycles.
6. Ulipristal acetate or any metabolite thereof for use according to any of claims 1-5 wherein a drug-free period comprises at least three menstruation cycles.
7. Ulipristal acetate or any metabolite thereof for use according to any of claims 1-6 wherein a drug-free period is not more than 6 months.
8. Ulipristal acetate or any metabolite thereof for use according to any of claims 1-7 wherein said ulipristal acetate or any metabolite thereof is to be administered daily.
9. Ulipristal acetate or any metabolite thereof for use according to any of claims 1-8 wherein ulipristal acetate or any metabolite thereof is to be administered in a daily amount of 5-15 mg.
10. Ulipristal acetate for use according to any of claims 1-9 wherein ulipristal acetate is to be administered in a daily amount of 10 mg.
11. A method of treating uterine fibroids comprising administering ulipristal acetate or any metabolite thereof in a therapeutically effective amount in subsequent treatment periods, which last 2-6 months and each treatment period is followed by a drug-free period.

12. A method according to claim 11 wherein a treatment period lasts 2-4 months.

13. A method according to any of claims 11-12 wherein a treatment period lasts 12 weeks.

14. A method according to any of claims 11-13 wherein a drug-free period comprises at least one menstruation cycle.

15. A method according to any of claims 11-14 wherein a drug-free period comprises at least two menstruation cycles.

16. A method according to any of claims 11-15 wherein a drug-free period comprises at least three menstruation cycles.

17. A method according to any of claims 11-16 wherein a drug-free period is not more than 6 months.

18. A method according to any of claims 11-17 wherein ulipristal acetate or any metabolite thereof is to be administered daily.

19. A method according to any of claims 11-18 wherein the daily amont is 5-15 mg ulipristal acetate or any metabolite thereof.

20. A method according to any of claims 11-19 wherein the daily amount is 10 mg ulipristal acetate.

21. Ulipristal acetate or any metabolite thereof in combination with a progestin for use in the treatment of uterine fibroids wherein ulipristal acetate or any metabolite thereof is to be administered for a treatment period of 2-6 months and progestin is to be administered for a subsequent treatment period of 5-30 days.

22. Ulipristal acetate or any metabolite thereof in combination with a progestin for use according to claim 21 wherein said compounds are to be administered in a repetitive manner comprising the followings:

a, administering ulipristal acetate;

b,thereafter administering progestin;

c,thereafter a drug-free period.

23. Ulipristal acetate or any metabolite thereof in combination with a progestin for use according to any of claims 21-22 wherein progestin is selected from the group comprising derivatives of 19-nortestosterone, derivatives of 17α-acetoxyprogesterone, levonorgestrel and dospirenone.

24. Ulipristal acetate or any metabolite thereof in combination with a progestin for use according to any of claims 21-23 wherein progestin is norethisterone acetate.

25. Ulipristal acetate or any metabolite thereof in combination with a progestin for use according to claim 24 wherein norethisterone acetate is to be administered in a daily amount of 5-15 mg.

26. Ulipristal acetate or any metabolite thereof in combination with a progestin for use according to ny of claims 24-25 wherein norethisterone acetate is to be administered in a daily amount of 10 mg.

27. Ulipristal acetate or any metabolite thereof in combination with a progestin for use according to any of claims 21-26 wherein ulipristal acetate or any metabolite thereof is to be administered in a daily amount of 5-15 mg.

28. Ulipristal acetate in combination with a progestin for use according to any of claims 21-27 wherein ulipristal acetate is to be administered in a daily amount of 10 mg.

29. Ulipristal acetate or any metabolite thereof in combination with a progestin for use according to any of claims 21-28 wherein ulipristal acetate or any metabolite thereof is to be administered for a treatment period of 2-4 months.

30. Ulipristal acetate or any metabolite thereof in combination with a progestin for use according to any of claims 21-29 wherein ulipristal acetate or any metabolite thereof is to be administered for a treatment period of 12 weeks.

31. Ulipristal acetate or any metabolite thereof in combination with a progestin for use according to any of claims 21-30 wherein progestin is to be administered for a treatment period of 10 days.

32. Ulipristal acetate in combination with a progestin for use according to any of claims 24-31 wherein ulipristal acetat is to be administered for a treatment period of 12 weeks and norethisterone acetate is to be administered for a treatment period of 10 days.

33. Ulipristal acetate or any metabolite thereof in combination with a progestin for use according to any of claims 22-32 wherein a drug-free period comprises at least one menstruation cycle.

34. Ulipristal acetate or any metabolite thereof in combination with a progestin for use according to any of claims 22-33 wherein a drug-free period comprises at least two menstruation cycles.

35. Ulipristal acetate or any metabolite thereof in combination with a progestin for use according to any of claims 22-34 wherein a drug-free period comprises at least three menstruation cycles.

36. A method of treating uterine fibroids comprising administering ulipristal acetate or any metabolite thereof for a treatment period of 2-6 months and administering a progestin administered for a subsequent treatment period of 5-30 days.

37. A method according to claim 16 wherein wherein said compounds are to be administered in a repetitive manner comprising the followings:

a, administering ulipristal acetate;

b,thereafter administering progestin;

c,thereafter a drug-free period.

38. A method according to any of claims 36-37 wherein progestin is selected from the group comprising derivatives of 19-nortestosterone, derivatives of 17α-acetoxyprogesterone, levonorgestrel and dospirenone.

39. A method according to any of claims 36-38 wherein progestin is norethisterone acetate.

40. A method according to claim 39 wherein norethisterone acetate is to be administered in a daily amount of 5-15 mg.

41. A method according to any of claims 39-40 wherein norethisterone acetate is to be administered in a daily amount of 10 mg.

42. A method according to any of claims 36-41 wherein is ulipristal acetate or any metabolite thereof to be administered in a daily amount of 5-15 mg.

43. A method according to any of claims 36-42 wherein is ulipristal acetate to be administered in a daily amount of 10 mg.

44. A method according to any of claims 36-43 wherein ulipristal acetate or any metabolite thereof is to be administered for a treatment period of 2-4 months.

45. A method according to any of claims 36-44 wherein ulipristal acetate or any metabolite thereof is to be administered for a treatment period of 12 weeks.

46. A method according to any of claims 36-45 wherein progestin is to be administered for a treatment period of 10 days.

47. A method according to any of claims 39-46 wherein ulipristal acetat is to be administered for a treatment period of 12 weeks and norethisterone acetate is to be administered for a treatment period of 10 days.

48. A method according to any of claims 36-47 wherein a drug-free period comprises at least one menstruation cycle.

49. A method according to any of claims 36-47 wherein a drug-free period comprises at least two menstruation cycles.

50. A method according to any of claims 36-47 wherein a drug-free period comprises at least three menstruation cycles.

CLAIMS

1. Use of ulipristal acetate or any metabolite thereof in the manufacture of a medicament for the treatment of uterine fibroids in a therapeutically effective amount, wherein said ulipristal acetate or any metabolite thereof is to be administered in subsequent treatment periods and a treatment period lasts 2-6 months and each treatment period is followed by a drug-free period.

2. Use of ulipristal acetate or any metabolite thereof according to claim 1 wherein a treatment period lasts 2-4 months.

3. Use of ulipristal acetate or any metabolite thereof according to of any claims 1-2 wherein a treatment period lasts 12 weeks.

4. Use of ulipristal acetate or any metabolite thereof according to any claims 1-3 wherein a drug-free period comprises at least one menstruation cycle.

5. Use of ulipristal acetate or any metabolite thereof according to any of claims 1-4 wherein a drug-free period comprises at least two menstruation cycles.

6. Use of ulipristal acetate or any metabolite thereof according to any of claims 1-5 wherein a drug-free period comprises at least three menstruation cycles.

7. Use of ulipristal acetate or any metabolite thereof according to any of claims 1-6 wherein a drug-free period is not more than 6 months.

8. Use of ulipristal acetate or any metabolite thereof according to any of claims 1-7 wherein said ulipristal acetate or any metabolite thereof is to be administered daily.

9. Use of ulipristal acetate or any metabolite thereof according to any of claims 1-8 wherein ulipristal acetate or any metabolite thereof is to be administered in a daily amount of 5-15 mg.

10. Use of ulipristal acetate according to any of claims 1-9 wherein ulipristal acetate is to be administered in a daily amount of 10 mg.

11. Use of ulipristal acetate or any metabolite thereof in combination with a progestin in the manufacture of a medicament for the treatment of uterine fibroids wherein ulipristal acetate or any metabolite thereof is to be administered for a treatment period

of 2-6 months and progestin is to be administered for a subsequent treatment period of 5-30 days.

12. Use of ulipristal acetate or any metabolite thereof in combination with a progestin according to claim 21 wherein said compounds are to be administered in a repetitive manner comprising the followings:

    a, administering ulipristal acetate;

    b, thereafter administering progestin;

    c, thereafter a drug-free period.

13. Use of ulipristal acetate or any metabolite thereof in combination with a progestin according to any of claims 21-22 wherein progestin is selected from the group comprising derivatives of 19-nortestosterone, derivatives of 17α-acetoxyprogesterone, levonorgestrel and dospirenone.

14. Use of ulipristal acetate or any metabolite thereof in combination with a progestin according to any of claims 21-23 wherein progestin is norethisterone acetate.

15. Use of ulipristal acetate or any metabolite thereof in combination with a progestin according to claim 24 wherein norethisterone acetate is to be administered in a daily amount of 5-15 mg.

16. Use of ulipristal acetate or any metabolite thereof in combination with a progestin according to any of claims 24-25 wherein norethisterone acetate is to be administered in a daily amount of 10 mg.

17. Use of ulipristal acetate or any metabolite thereof in combination with a progestin according to any of claims 21-26 wherein ulipristal acetate or any metabolite thereof is to be administered in a daily amount of 5-15 mg.

18. Use of ulipristal acetate in combination with a progestin according to any of claims 21-27 wherein ulipristal acetate is to be administered in a daily amount of 10 mg.

19. Use of Ulipristal acetate or any metabolite thereof in combination with a progestin according to any of claims 21-28 wherein ulipristal acetate or any metabolite thereof is to be administered for a treatment period of 2-4 months.

20. Use of ulipristal acetate or any metabolite thereof in combination with a progestin according to any of claims 21-29 wherein ulipristal acetate or any metabolite thereof is to be administered for a treatment period of 12 weeks.

21. Use of ulipristal acetate or any metabolite thereof in combination with a progestin according to any of claims 21-30 wherein progestin is to be administered for a treatment period of 10 days.

22. Use of ulipristal acetate in combination with a progestin according to any of claims 24-31 wherein ulipristal acetat is to be administered for a treatment period of 12 weeks and norethisterone acetate is to be administered for a treatment period of 10 days.

23. Use of ulipristal acetate or any metabolite thereof in combination with a progestin according to any of claims 22-32 wherein a drug-free period comprises at least one menstruation cycle.

24. Use of ulipristal acetate or any metabolite thereof in combination with a progestin according to any of claims 22-33 wherein a drug-free period comprises at least two menstruation cycles.

25. Use of ulipristal acetate or any metabolite thereof in combination with a progestin according to any of claims 22-34 wherein a drug-free period comprises at least three menstruation cycles.